Actio Biosciences

News

Jazz builds in epilepsy with $1.3bn Actio acquisition

Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.

News

Double IPOs headline this week's biotech financings

This week saw two $250 million-plus initial public offering (IPO) filings for Neumora Therapeutics and RayzeBio, plus a record third-round financing for Generate Biomedici

News

GSK planning 1,200 job cuts in Belgium, says paper

GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks